Nurix pushes its degrader forward
The company will start its confirmatory bexobrutideg study in June.
Fuelled by Pfizer, Triana enters the clinic
The industry’s first ALK degrader starts its first human study.
Revealed: Merck’s double bet on TROP2
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
Licensing analysis: Chinese deals abound
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
SystImmune starts another first-line phase 3
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
M&A analysis: Merck and Gilead splash the cash
The groups spend big on Terns and Arcellx.
FDA red and green lights: March 2026
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
